Cotización Entero Therapeutics - ENTO

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Último Precio

0.545

Postura de Compra

0.5356

Postura de Venta

0.55

Volume Operado de la Acción

529,922

0.4249 Rango del Día 0.615

0.185 Rango de 52 semanas 3.16

Precio Anterior

0.63

Precio de Apertura

0.615

Hora

100

0.545

Última hora de negociación

12:59:54

Volumen promedio (3 m)

423,051

Volumen financiero

US$ 252,100

Precio Promedio Ponderado

0.47573

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy Special editorial highlights the...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-0.155	-22.1428571429	0.7	0.716199	0.4249	406257	0.63105266	CS
4	0.01	1.8691588785	0.535	0.8655	0.4249	279408	0.66557704	CS
12	0.125	29.7619047619	0.42	0.8655	0.28	423051	0.56034707	CS
26	-2.415	-81.5878378378	2.96	3.16	0.185	480568	0.47720261	CS
52	-2.415	-81.5878378378	2.96	3.16	0.185	480568	0.47720261	CS
156	-2.415	-81.5878378378	2.96	3.16	0.185	480568	0.47720261	CS
260	-2.415	-81.5878378378	2.96	3.16	0.185	480568	0.47720261	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
MTEMMolecular Templates Inc	US$ 0.636 (97.45%)	290.47M
QUBTQuantum Computing Inc	US$ 4.4712 (68.09%)	186.43M
SHOTWSafety Shot Inc	US$ 0.1685 (53.04%)	6.47k
OMEROmeros Corporation	US$ 6.1201 (46.06%)	11.93M
IFRXInflaRx NV	US$ 2.335 (36.55%)	1.47M
SOWGSow Good Inc	US$ 4.03 (-58.92%)	2.29M
WCTWellchange Holdings Company Limited	US$ 4.38 (-44.56%)	755.1k
NVCTNuvectis Pharma Inc	US$ 5.951 (-44.23%)	1.37M
TRNRInteractive Strength Inc	US$ 3.84 (-34.13%)	1.13M
OPRXOptimizeRx Corporation	US$ 4.13 (-32.85%)	1.41M
ELABElevai Labs Inc	US$ 0.0268 (8.50%)	1.64B
XTIAXTI Aerospace Inc	US$ 0.0639 (11.71%)	331.82M
MTEMMolecular Templates Inc	US$ 0.636 (97.45%)	290.47M
SVMHSRIVARU Holding Ltd	US$ 0.0272 (12.40%)	228.28M
QUBTQuantum Computing Inc	US$ 4.4712 (68.09%)	190.7M